Get the Stockscreener App
18.43
1.02%
-0.19
After Hours:
18.53
0.10
+0.54%
Overview
News
Price History
Option Chain
Financials
Why KVUE Down?
Discussions
Forecast
Dividend History
Kenvue Inc stock is traded at $18.43, with a volume of 56.11M.
It is down -1.02% in the last 24 hours and down -13.64% over the past month.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
See More
Previous Close:
$18.62
Open:
$18.75
24h Volume:
56.11M
Relative Volume:
2.78
Market Cap:
$35.37B
Revenue:
$15.14B
Net Income/Loss:
$1.42B
P/E Ratio:
24.91
EPS:
0.74
Net Cash Flow:
$1.63B
1W Performance:
-11.01%
1M Performance:
-13.64%
6M Performance:
-21.31%
1Y Performance:
-19.38%
1-Day Range:
$18.20
$18.93
1-Week Range:
$17.14
$20.82
52-Week Range:
$17.14
$25.17
Kenvue Inc Stock (KVUE) Company Profile
Name
Kenvue Inc
Sector
Industry
Phone
908-874-1200
Address
1 KENVUE WAY, SUMMIT
Compare KVUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KVUE
Kenvue Inc
|
18.43 | 35.73B | 15.14B | 1.42B | 1.63B | 0.74 |
|
PG
Procter Gamble Co
|
159.01 | 374.83B | 84.28B | 16.07B | 14.05B | 6.51 |
|
UL
Unilever Plc Adr
|
64.00 | 157.68B | 64.99B | 6.71B | 6.53B | 2.4495 |
|
CL
Colgate Palmolive Co
|
84.19 | 68.80B | 20.00B | 3.05B | 3.37B | 3.56 |
|
KMB
Kimberly Clark Corp
|
129.78 | 43.09B | 18.88B | 2.38B | 2.10B | 7.26 |
Kenvue Inc Stock (KVUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Redburn Atlantic | Neutral |
| Mar-24-25 | Initiated | Evercore ISI | In-line |
| Jan-06-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-12-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-24-24 | Initiated | Jefferies | Buy |
| Sep-24-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-28-24 | Resumed | Citigroup | Neutral |
| Apr-11-24 | Initiated | Bernstein | Underperform |
| Apr-03-24 | Initiated | William Blair | Mkt Perform |
| Mar-01-24 | Resumed | Goldman | Neutral |
| Nov-17-23 | Initiated | Piper Sandler | Neutral |
| Sep-11-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-07-23 | Initiated | Canaccord Genuity | Buy |
| Sep-06-23 | Initiated | Argus | Hold |
| Aug-24-23 | Upgrade | Goldman | Neutral → Buy |
| Jul-25-23 | Initiated | Edward Jones | Buy |
| Jun-01-23 | Initiated | HSBC Securities | Hold |
| May-30-23 | Initiated | BofA Securities | Buy |
| May-30-23 | Initiated | Citigroup | Neutral |
| May-30-23 | Initiated | Deutsche Bank | Hold |
| May-30-23 | Initiated | Exane BNP Paribas | Neutral |
| May-30-23 | Initiated | Goldman | Neutral |
| May-30-23 | Initiated | JP Morgan | Overweight |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Initiated | UBS | Neutral |
View All
Kenvue Inc Stock (KVUE) Latest News
Goldman Sachs maintains Kenvue stock rating amid potential Tylenol report - Investing.com
Kenvue Drops on Report RFK Jr. Will Link Tylenol to Autism - MSN
WSJ: Kenvue rejects reported HHS link of autism to painkiller - WBAL-TV
RFK Jr.'s planned report linking Tylenol to autism crashes shares of parent company Kenvue - Fortune
Kenvue Falls After Report on Tylenol, Autism Link - Yahoo Finance
Buy Rating on Kenvue, Inc. Amidst Minimal Legal Risks and Overreaction to Tylenol Concerns - TipRanks
Canaccord Genuity reiterates Buy rating on Kenvue stock amid legal concerns - Investing.com
JPMorgan maintains Overweight rating on Kenvue stock amid acetaminophen concerns - Investing.com
Wegmans On Board with 2D Barcodes; Kenvue Will be Ready - Healthcare Packaging
JPMorgan Defending Kenvue Inc (KVUE): 'Tylenol products already direct patients who are pregnant or breastfeeding to consult their healthcare provider before use' - StreetInsider
Bank of America sees 'attractive entry point' in Kenvue after Tylenol controversy sparks sell-off - CNBC
Kenvue Inc put buyer realizes 365% same-day gains - TipRanks
Jobs report fallout, Kenvue's sell-off, mortgage rate slide and more in Morning Squawk - CNBC
Kenvue Seen As Attractive Buy By BofA After Stock Dip Following Report On Tylenol Autism Link - Stocktwits
Evercore ISI cuts Kenvue stock price target to $23 on Tylenol concerns - Investing.com
Positive Buy Rating for Kenvue, Inc. Amid Favorable Legal and Regulatory Developments - TipRanks
Evercore ISI Adjusts Price Target on Kenvue to $23 From $25, Keeps In Line Rating - MarketScreener
Kenvue stock falls 9.4% on WSJ report linking Tylenol to autism - Investing.com
Ancora Advisors LLC Boosts Position in Kenvue Inc. $KVUE - MarketBeat
Is Kenvue Inc. a cyclical or defensive stockQuarterly Growth Report & Community Consensus Stock Picks - beatles.ru
Baird Financial Group Inc. Sells 155,943 Shares of Kenvue Inc. $KVUE - MarketBeat
Royal Bank of Canada Sells 710,749 Shares of Kenvue Inc. $KVUE - MarketBeat
Sen. Sheldon Whitehouse Sells Kenvue Inc. (NYSE:KVUE) Stock - MarketBeat
Evercore ISI maintains Kenvue stock rating amid Tylenol autism study concerns - Investing.com
Eventide Asset Management LLC Makes New Investment in Kenvue Inc. $KVUE - MarketBeat
BofA Securities reiterates Buy on Kenvue stock amid Tylenol concerns - Investing.com
Amundi Increases Position in Kenvue Inc. $KVUE - MarketBeat
Shares of Kenvue, a U.S. company, have plummeted amid controversy surrounding the well-known cold medication Tylenol. - 富途牛牛
Kenvue Inc. $KVUE Shares Sold by Jump Financial LLC - MarketBeat
Maverick Capital Ltd. Purchases New Holdings in Kenvue Inc. $KVUE - MarketBeat
Harris Associates L P Has $644.62 Million Stock Position in Kenvue Inc. $KVUE - MarketBeat
Kenvue Inc (KVUE) Stock: Shares Fall 9% After Tylenol–Autism Link Reports - CoinCentral
Edmond DE Rothschild Holding S.A. Raises Position in Kenvue Inc. $KVUE - MarketBeat
DoubleLine ETF Adviser LP Has $2.08 Million Stock Position in Kenvue Inc. $KVUE - MarketBeat
Concentric Capital Strategies LP Acquires Shares of 155,390 Kenvue Inc. $KVUE - MarketBeat
Kenvue Inc. $KVUE Shares Sold by Curi RMB Capital LLC - MarketBeat
Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism - Sherwood News
Kenvue Inc. $KVUE Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
Federation des caisses Desjardins du Quebec Purchases 32,746 Shares of Kenvue Inc. $KVUE - MarketBeat
The Manufacturers Life Insurance Company Sells 372,296 Shares of Kenvue Inc. $KVUE - MarketBeat
Where is Tylenol made? RFK Jr. links autism to Montco-based drug maker; what to know - PhillyBurbs
Can Kenvue Inc. be the next market leader2025 Major Catalysts & AI Optimized Trading Strategy Guides - خودرو بانک
What institutional flow reveals about Kenvue Inc.Rate Hike & Technical Confirmation Trade Alerts - Newser
What is Kenvue Inc.’s valuation compared to sectorWeekly Stock Analysis & Risk Controlled Stock Alerts - خودرو بانک
Canada Pension Plan Investment Board Sells 2,749,266 Shares of Kenvue Inc. $KVUE - MarketBeat
Fibonacci Levels Suggest Recovery for Kenvue Inc.Earnings Risk Report & Weekly Top Performers Watchlists - beatles.ru
Kenvue shares dip 10% as RFK Jr. connects Tylenol use in pregnancy with autism - R&D World
Tylenol Potential Safety Claims Loom Over Kenvue’s Summit NJ HQ - TAPinto
Momentum divergence signals in Kenvue Inc. chartJuly 2025 Big Picture & Stepwise Entry and Exit Trade Signals - Newser
Kenvue Inc. (NYSE:KVUE) Receives $24.38 Consensus Target Price from Brokerages - MarketBeat
Wall Street ends down slightly after weak jobs data - MarketScreener
Kenvue Inc Stock (KVUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
2.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):